Kathleen Roeder
Acute Care · Cincinnati, OHNPI 1326099839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$986
- Lilly USA, LLC$734
- GSK$638
- AbbVie$637
- Amgen$355
- Pfizer$337
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,657100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $986 |
| Lilly USA, LLC | 51 | $734 |
| GSK | 42 | $638 |
| AbbVie | 59 | $637 |
| Amgen | 23 | $355 |
| Pfizer | 24 | $337 |
| Bayer | 17 | $273 |
| Amarin Pharma, Inc. | 13 | $203 |
| Novo Nordisk | 21 | $196 |
| Esperion Therapeutics, Inc. | 13 | $195 |
| Exact Sciences | 9 | $168 |
| Kowa Pharmaceuticals America, Inc. | 8 | $107 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| Johnson & Johnson | 6 | $84 |
| Idorsia Pharmaceuticals US Inc | 4 | $64 |
| Novartis | 4 | $64 |
| IBSA Pharma Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Boehringer Ingelheim | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Phadia US Inc. | 2 | $35 |
| Vifor Pharma, Inc. | 2 | $30 |
| Medtronic | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Corcept Therapeutics | 1 | $21 |
| Teleflex LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,657 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 70 | $89,518 |
| OzempicSemaglutide | 32 | $43,392 |
| FarxigaDapagliflozin Propanediol | 22 | $25,207 |
| JanuviaSitagliptin Phosphate | 14 | $18,605 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,794 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,829 |
| Levothyroxine Sodium | 191 | $1,684 |
| Gabapentin | 82 | $1,133 |
| Pregabalin | 50 | $883 |
| Eszopiclone | 25 | $713 |
| Zolpidem Tartrate | 84 | $684 |
| Atorvastatin Calcium | 89 | $659 |
| Omeprazole | 65 | $504 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $456 |
| Metoprolol Succinate | 25 | $417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $734 | $89,51870 claims |
| Novo NordiskOzempic | $196 | $43,39232 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $986 | $39,00140 claims |
| GSKIncruse Ellipta | $638 | $3,82911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Cincinnati
- Julie LurieCincinnati$13K
- Laura LangenhopCincinnati$8K
- Jennifer ClarkCincinnati$7K
- Amy HawkinsCincinnati$7K
- Rebecca BlantonCincinnati$6K
- Carrie MyersCincinnati$6K
- Nicole BrownCincinnati$5K
- Donna AbdelnourCincinnati$5K
- Bonnie AlbertCincinnati$4K
- Jessica HendrixCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.